Inhaled corticosteroids (ICSs) are a key incorporation to COPD treatment strategies. Jeffrey D. Dunn, PharmD, MBA: ICSs [inhaled corticosteroids] haven’t shown much evidence in impacting the course of ...

Please provide your email address to receive an email when new articles are posted on . Moving from a low-dose inhaled corticosteroid to a medium-dose inhaled corticosteroid plus a long-acting beta ...

The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

In patients with chronic obstructive pulmonary disease (COPD), new initiation of beta2-agonist therapy, such as short-acting beta2-agonists (SABA), long-acting beta2-agonists (LABA), or inhaled ...

Please provide your email address to receive an email when new articles are posted on . Fluticasone-based inhaled corticosteroid treatment substantially changed airway microbiome diversity in patients ...

A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...

A Cochrane systematic review has found new moderate-quality evidence that tiotropium + long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS) combination therapy reduces hospital admission for ...

Additional data presentations for fluticasone furoate and vilanterol trifenatate support the potential of developmental combination treatment, Relovair, in COPD and asthma LONDON and SOUTH SAN ...

Photomicrograph of salivary gland of a person with Sjögren’s syndrome, characterized by the abnormal migration of of lymphocytes T and B. Here the lymphocytes T and B appear in mauve. Investigators ...

GlaxoSmithKline plc (LSE/NYSE:GSK) today announced publication of results from the 'LABA' (long acting beta2-agonist) safety study, AUSTRI (SAS115359) in the New England Journal of Medicine (NEJM).